Clin2
NCT05424692Possibly a fitRecruiting

Test tumor drug sensitivity to guide after-surgery colon cancer care

Colon CancerRectal CancerChemotherapy EffectPTCExon Mutation

Part of Cancer, Digestive system clinical trials.

This study looks at whether testing a small tumor sample can identify which medicines are more likely to work for colorectal cancer after surgery. The results are used to help choose the best “after-surgery” treatment plan, when you have not had chemotherapy before surgery.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are 18 to 75 years old and can take part regardless of sex.
  • You have colorectal cancer confirmed by pathology or cytology, and you’re planning after-surgery (adjuvant) treatment.
  • You have had surgery to remove the cancer (radical surgery) and you did not receive any treatment before surgery (no neoadjuvant therapy).
  • There is at least one tumor spot the team can measure and test using a tumor sample.
  • You are not living with spread to distant sites (no metastasis).
  • You can provide tumor tissue, and you are able to follow study instructions and visit requirements.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05534087Recruiting· Phase 3
Blood test guided chemo after colon cancer surgery

This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.

Busan
NCT05797467Recruiting· Phase 3
After-surgery chemo plus targeted therapy for colon cancer

This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.

Guangzhou, Guangdong
NCT07562711Recruiting· Phase 2
Blood Test to Guide Chemotherapy After Colon Cancer Surgery

This study uses a simple blood test to detect cancer DNA after surgery for early-stage colon cancer. The goal is to help doctors decide whether chemotherapy is truly needed based on the blood test results, rather than giving it to everyone.

Shanghai
NCT07562659Recruiting· Phase 2
Blood Test to Guide Chemotherapy After Colon Cancer Surgery

This study helps doctors decide whether you need chemotherapy after colon cancer surgery by checking for cancer DNA in your blood. The goal is to give chemotherapy only to patients who truly need it, based on what the blood test shows.

Shanghai
NCT07562490Recruiting· Phase 2
Blood Test to Guide Chemotherapy After Colorectal Cancer Surgery

This study tests whether a special blood test (looking for cancer DNA) can help doctors decide if you need chemotherapy after colorectal cancer surgery. The goal is to avoid unnecessary chemotherapy while making sure patients who need it get treated.

Shanghai
NCT05870800Recruiting· Phase 2
Study Immunotherapy and Chemotherapy Before Colon Surgery

This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.

Houston, Texas

Hear when a new Colon Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.